AMPEL BioSolutions
AMPEL BioSolutions is a biomedical company focused on personalized precision medicine for autoimmune and inflammatory diseases. They utilize their AMPEL Genomic Platform (AGP®), which leverages RNA analytics and predictive AI, to evaluate disease status, identify cellular functions and pathways, and predict disease flares and drug targets. Their core product is LuGENE®, a genomic blood test for Lupus that predicts flares and guides drug selection. The company also has future products in development for dermatology (DermaGENE®) and wellness (WellGENETM). AMPEL collaborates with pharmaceutical and precision medicine companies for co-development, licensing, and biomarker opportunities across various disease areas like Lupus, Dermatology, Cardiology, and Nephrology. The company's platform is powered by an exclusive curated database of over 25,000 autoimmune patient gene expression profiles, which fuels their machine learning predictions.
AMPEL BioSolutions
AMPEL BioSolutions is a biomedical company focused on personalized precision medicine for autoimmune and inflammatory diseases. They utilize their AMPEL Genomic Platform (AGP®), which leverages RNA analytics and predictive AI, to evaluate disease status, identify cellular functions and pathways, and predict disease flares and drug targets. Their core product is LuGENE®, a genomic blood test for Lupus that predicts flares and guides drug selection. The company also has future products in development for dermatology (DermaGENE®) and wellness (WellGENETM). AMPEL collaborates with pharmaceutical and precision medicine companies for co-development, licensing, and biomarker opportunities across various disease areas like Lupus, Dermatology, Cardiology, and Nephrology. The company's platform is powered by an exclusive curated database of over 25,000 autoimmune patient gene expression profiles, which fuels their machine learning predictions.